Teladoc Health

teladochealth.com

Teladoc Health is the global virtual care leader, offering the only comprehensive virtual care solution spanning telehealth, expert medical, and licensed platform services. Through our award-winning consumer experience brands – Advance Medical, Best Doctors, BetterHelp, HealthiestYou, and Teladoc – we help millions of people around the world resolve their healthcare needs with confidence.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

news image

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

news image

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More

CERTEST BIOTEC AND BD ANNOUNCES THE VIASURE SARS-COV-2 (N1 + N2) REAL TIME PCR DETECTION KIT ADAPTED FOR THE BD MAX™

CerTest | October 21, 2020

news image

CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit adapted for the BD MAX™ System has been CE marked* to the IVD Directive (98/79/EC). This kit allows BD MAX™ System users to run a single module that tests concurrently for COVID-19 and Influenza (Flu) and Respiratory Syncytial Virus (RSV). "The new CerTest kit will provide rapid C...

Read More

CELL AND GENE THERAPY

MODERNA AND ALDEVRON ANNOUNCE EXPANDED COLLABORATION FOR MRNA VACCINE AND THERAPEUTIC PIPELINE

Moderna, Aldevron | May 25, 2021

news image

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA, and recombinant proteins used for vaccines, gene and cell therapy, gene editing, and diagnostic applications, have announced an expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in mRNA therapeutics and vaccines. Aldevron will specifically provide plasmid DNA to act as th...

Read More
news image

CELL AND GENE THERAPY

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More
news image

CERTEST BIOTEC AND BD ANNOUNCES THE VIASURE SARS-COV-2 (N1 + N2) REAL TIME PCR DETECTION KIT ADAPTED FOR THE BD MAX™

CerTest | October 21, 2020

CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit adapted for the BD MAX™ System has been CE marked* to the IVD Directive (98/79/EC). This kit allows BD MAX™ System users to run a single module that tests concurrently for COVID-19 and Influenza (Flu) and Respiratory Syncytial Virus (RSV). "The new CerTest kit will provide rapid C...

Read More
news image

CELL AND GENE THERAPY

MODERNA AND ALDEVRON ANNOUNCE EXPANDED COLLABORATION FOR MRNA VACCINE AND THERAPEUTIC PIPELINE

Moderna, Aldevron | May 25, 2021

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA, and recombinant proteins used for vaccines, gene and cell therapy, gene editing, and diagnostic applications, have announced an expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in mRNA therapeutics and vaccines. Aldevron will specifically provide plasmid DNA to act as th...

Read More